Alzheimer’s disease (AD) is the fifth leading cause of death in adults over the age of 65, and researchers from Brigham and Women’s Hospital are making strides in treating the neurodegenerative disease. The researchers compared deep brain stimulation (DBS) targets in AD patients previously treated at seven international sites, finding that stimulating the intersection of two brain networks correlated with better patient outcomes than stimulating nearby sites.
DBS is a neurosurgical technique that involves electrically exciting brain circuits to alleviate symptoms of disorders such as Parkinson’s disease and obsessive-compulsive disorder. The technique has produced mixed results in the treatment of AD, with variation in cognitive outcomes. These different outcomes may be due to discrepancies in electrode placements across patients.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
“Not many Alzheimer’s patients have been treated with DBS, and so isolating a targetable network and showing that it could be predictive of patient outcomes was exciting,” says corresponding author Andreas Horn, MD, PhD, of the Center for Brain Circuit Therapeutics. “We refined an optimal DBS site, which future clinical trials of DBS may now use, going forward. If more patients are stimulated at this region, we may see clearer evidence across the group supporting the effectiveness of DBS.”
For the paper published in Nature Communications, the team wanted to know whether differences in electrode placement on Alzheimer’s patients during DBS could explain why some patients’ cognitive function improved while others deteriorated. To do this, they examined 46 patients who received DBS to the fornix, an essential structure involved in memory formation. They also used specialized software to register DBS sites from individual patients into a standardized map of the brain.
From there, they calculated the target associated with optimal clinical outcomes and determined what modulations of local tracts and whole-brain networks led to the best results. Cognitive improvement was associated with DBS to the direct interface between the fornix and the bed nucleus of the stria terminalis, with tract connections to the circuit of Papez playing a role as well.
The researchers validated their findings in a test cohort of 18 patients whose data had been excluded from the initial stages of the research. They developed a model that could accurately determine clinical outcomes in these patients based on where electrodes had been placed during their DBS procedures.
The authors emphasize that this study is retrospective and that prospective validation is required to further validate their findings. They emphasize that neurodegeneration will progress even in patients responding well to fx-DBS but that this procedure may lessen their intense symptomology.
As clinical trials progress, the team hopes to collaborate with other centers conducting DBS to better understand targetable networks for AD. They also want to study the specific circuits involved in memory formation based on stroke lesions that result in cognitive decline.
“The data we used in this study are unique, and we are grateful that the team entrusted us with it so we could use the methods we have developed over the last ten years to identify the most important sites in the brain for DBS in AD,” says Horn. “While this is still basic science, it may provide hope for potential treatments that, if applied correctly, could lead to symptom improvements.”